(Adnkronos) - “Le copiose evidenze real life” sull’impiego degli anticorpi monoclonali per il trattamento dell’emicrania “hanno addirittura aumentato, rispetto ai trial clinici randomizzati, i risultati in termini di efficacia, di miglioramento della qualità di vita e di riduzione della disabilità”. Così Fabrizio Vernieri, responsabile Uos Cefalee e Neurosonologia del policlinico universitario Campus Bio-Medico e professore di Neurologia dell’università Campus Bio-Medico di Roma, all’incontro ‘Empatia, empowerment, emicrania: vivere la vita’, organizzato a Roma da Organon Italia.
Category
🗞
NewsTranscript
00:00We are talking about real-life evidence, because randomized trial clinics have already shown
00:10the effectiveness, the tolerability, the safety of monoclonal antibodies.
00:14The real-life evidence that has happened in these years, that have become copious and
00:20that represent the results of the clinical practice that we do daily in our
00:26patients, have even increased the results in terms of effectiveness, quality of life,
00:33disability in patients treated with monoclonal antibodies.
00:38So this has valued the fact that these treatments, for the first time in a selective way,
00:44treating patients at high frequency and with chronic hemicrania, have clearly improved
00:50the quality of life of hemicranial patients.